HC Bioscience Completes Nearly RMB 500 Million Series C Financing to Advance Nucleic Acid Therapeutics and Complex Injectables
Haichang Biotech
Innovative Formulation Developer
Kexing Biopharm
Developer, Manufacturer, and Marketer of Recombinant Protein Drugs and Microecological Preparations
Recently, Zhejiang Haichang Biotech Co., Ltd.("Haichang Biotech" for short)Haichang Biotech Announces Completion of Series C Financing. The total amount of this round of financing is nearly 500 million RMB, led by SDIC (Guangdong) Venture Capital Fund Partnership For Transformation of Scientific and Technological, with participation from Jianyuan Shunda (Hangzhou) Equity Investment Fund, Dongguan Songshan Lake Science City Equity Investment Fund, Zhejiang Province "4+1" Biopharmaceuticals and High-end Medical Devices Industry Fund, and Kexing Biopharm Co., Ltd. This round of financing will focus on the development of nucleic acid innovative drug pipelines, novel extrahepatic delivery systems, clinical trials, and accelerating the construction of production bases and capacity.
As a national-level specialized and innovative"Little Giant" Enterprise, Haichang Biotech Focuses on the Development and Industrial Application of Drug Delivery System Technologies, Building a Proprietary Intellectual Property PortfolioQTsome®and other technical platforms. Currently, the company has successfully broken through the international nucleic acid delivery patent barriers, achieving key"Throat-grabbing" technology breakthrough. A novel small nucleic acid drug for primary liver cancer developed based on the company's existing technology platform.HC0301Has entered ChinaCountries (including Hong Kong, China), the United States, and other international multicentersII...has entered the clinical stage, becoming one of the fastest progressing pipelines in the global small nucleic acid precision oncology treatment field.The world's first, based on lipid nanoparticles (QTsome®) The next-generation TLR9 immunostimulant HC016 lipid complex injection, developed by Haichang Biotech, has received IND approvals in both China and the U.S.Entering ClinicalIPhase, with best-in-class (BIC) potential, showcasing strong innovative capabilities. At the same time, the company has several potential first-in-class (FIC) Nucleic Acid Drug AdministrationLines, and in vivo edited cell therapy innovative therapies.
In the field of complex injectables, the company's key product is an injectionUsing paclitaxel (albumin-bound), currently inChina, the European Union, the United Kingdom, Peru, and nearly40Approved for marketing in multiple countries and regions. The dual production sites of CR Double-Crane Tiantong Pharmaceutical, Kexing Biopharm, and others have simultaneously passed the EU certification.cGMPCertification, leading the internationalization process of China's high-end formulations, with several complex injectable products即将上市.
Dr. Xiaobin Zhao, Chairman and Founder of Haichang Biotech, stated:This round of financing reflects the market's full recognition of the company's core technology advantages and strategic value, and will also provide strong support for Haichang Biotech's long-term development strategy. We will use delivery platforms such as QTsome® as a strategic fulcrum to build a closed-loop system for the research, production, and commercialization of high-end complex injectables and nucleic acid innovative drugs. By empowering core products with capital for global layout, and using technological innovation as the driving force, we will continuously break through key industry technology bottlenecks and contribute to the transformation of the global pharmaceuticals industry.
This round of financing was obtained by SDIC Venture Capital and CCB.Investment, Songshan Lake Venture Capital, Heda Financial Services, Kexing Biopharm, and other institutions’ support, forming"National Capital Strategy Leads+Local Industrial Capital Synergy+"A three-dimensional capital matrix for industrial chain co-construction," focusing on accelerating the transformation of major scientific and technological achievements, industrial规模化 application, fostering and strengthening strategic emerging industries, and building industry benchmark enterprises. The company will continue to introduce strategic investments from domestic and international biopharmaceutical professional investment institutions to construct a "technology"-Capital-"Trinity of Industry" global innovation ecosystem. Through the efficient integration of strategic resources and the steady advancement of global layout, the company is comprehensively enhancing its core competitiveness, aiming to become a key player in the field of international pharmaceutical innovation, providing innovative treatment solutions with greater clinical value for patients worldwide.
SDIC Venture Capital is a venture capital fund management company specially established by the State Development & Investment Corporation (SDIC) to implement the national innovation-driven development strategy, deepen the comprehensive strategic cooperation with the Ministry of Science and Technology, and accelerate the transfer and transformation of national scientific and technological achievements in a market-oriented manner. SDIC (Guangdong) Venture Capital Fund Partnership For Transformation of Scientific and Technological is initiated by the Ministry of Science and Technology, SDIC, local governments, financial institutions, and other parties, with SDIC Venture Capital serving as the fund manager. The fund consistently focuses on the investment goal of transforming scientific and technological achievements, concentrating on key areas such as advanced manufacturing, electronic information, biomedicine, materials, and energy. It continuously promotes the independent innovation of core technologies to achieve breakthroughs and build a sound investment ecosystem for the transformation of scientific and technological achievements.
Jianyuan Shunda (Hangzhou) Equity Investment Fund Partnership (Limited Partnership), initiated and established by Jianxin Financial Asset Investment Co., Ltd., a wholly-owned subsidiary of China Construction Bank, focuses on technological innovation. The fund prioritizes investment in cutting-edge sectors such as artificial intelligence, intelligent manufacturing, the Internet of Things, biomedicine, high-end equipment, new materials, and green energy. Leveraging the comprehensive financial service capabilities of a major state-owned bank, it establishes a "technology-industry-finance" linkage mechanism to support Hangzhou's development of new productive forces.
Dongguan Songshan Lake Science City Equity Investment Partnership (Limited Partnership) is a pre-IPO fund managed by Dongguan Songshan Lake Science City Co., Ltd. ("Science City Company"), focusing on industrial investment and industry incubation within Songshan Lake’s "1+4+1+X" modern industrial system. Science City Company is a state-owned enterprise in the Songshan Lake Park, shouldering the corporate mission of development and construction, park industrial development, and urban comprehensive operations, with a focus on five main business sectors: industrial operations, industrial investment, commerce and cultural tourism, engineering construction, and urban operations.
Zhejiang Province "4+1" Biopharmaceuticals and High-End Medical Devices Industry Fund was established in October 2023, with a total scale of 5 billion yuan.(Initial scale of 2 billion yuan), with the subsidiary of Qiantang Industrial Group and Hedda Financial Services' private equity fund management company acting as the manager and GP1, and Jintou Shengyuan under Zhejiang Financial Holdings as GP2 jointly participating in management. The fund focuses on key areas of Zhejiang Province's modern consumption and large health industry, committed to building a full industrial chain ecosystem. It has currently invested in 17 projects and 5 sub-funds, with an investment amount of 1.189 billion yuan. Its healthcare investments have been awarded the "Top New Healthcare Investment Institution of 2024" by the Joyful List.
Kexing Biopharm Co., Ltd.(abbreviation: Kexing Biopharm, stock code: 688136)Kexing Biopharm is an innovative international biopharmaceutical company mainly engaged in the research, development, production, and sales of recombinant protein drugs and microecological preparations. Focusing on therapeutic areas such as antiviral, oncology and immunology, hematology, gastroenterology, and degenerative diseases, the company has established cutting-edge biotechnology platforms for novel proteins, new antibodies, and nucleic acid drugs. It adheres to a dual-driven platform-based development model of "innovation + internationalization," while exploring the wide application of biotechnology in the healthcare sector, actively fostering and incubating new industries, and striving to become a leader in high-quality biopharmaceuticals to serve patients worldwide.
Haichang Biotech, located in China Medical Valley, Hangzhou, is a national-level specialized and innovative "little giant" enterprise that integrates research, production, and sales, with biopharmaceutical technology innovation as its core driving force. Adhering to the core values of "sharing, progress, truth-seeking, and pragmatism," the company focuses on the technical development and industrial application of drug delivery systems, with a product pipeline covering multiple disease areas including cancer, metabolic diseases, pain management, and infectious diseases.
